Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Structure-activity relationship of novel macrocyclic biased apelin receptor agonists.

Murza A, Sainsily X, Côté J, Bruneau-Cossette L, Besserer-Offroy É, Longpré JM, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

Org Biomol Chem. 2017 Jan 4;15(2):449-458. doi: 10.1039/c6ob02247b.

PMID:
27924341
2.

The hypotensive effect of activated apelin receptor is correlated with β-arrestin recruitment.

Besserer-Offroy É, Bérubé P, Côté J, Murza A, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Marsault É, Sarret P.

Pharmacol Res. 2018 May;131:7-16. doi: 10.1016/j.phrs.2018.02.032. Epub 2018 Mar 9.

PMID:
29530600
3.

C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action.

Murza A, Besserer-Offroy É, Côté J, Bérubé P, Longpré JM, Dumaine R, Lesur O, Auger-Messier M, Leduc R, Sarret P, Marsault É.

J Med Chem. 2015 Mar 12;58(5):2431-40. doi: 10.1021/jm501916k. Epub 2015 Feb 24.

PMID:
25668242
4.

Cardiac action of the first G protein biased small molecule apelin agonist.

Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP.

Biochem Pharmacol. 2016 Sep 15;116:63-72. doi: 10.1016/j.bcp.2016.07.018. Epub 2016 Jul 27.

5.

Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling.

Galon-Tilleman H, Yang H, Bednarek MA, Spurlock SM, Paavola KJ, Ko B, To C, Luo J, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD.

J Biol Chem. 2017 Feb 3;292(5):1925-1933. doi: 10.1074/jbc.M116.748103. Epub 2016 Dec 19.

6.

Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling.

Chen X, Bai B, Tian Y, Du H, Chen J.

J Biol Chem. 2014 Nov 7;289(45):31173-87. doi: 10.1074/jbc.M114.574020. Epub 2014 Sep 30.

7.

Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Yang P, Maguire JJ, Davenport AP.

Trends Pharmacol Sci. 2015 Sep;36(9):560-7. doi: 10.1016/j.tips.2015.06.002. Epub 2015 Jul 1. Review.

8.

A Systematic Approach to Identify Biased Agonists of the Apelin Receptor through High-Throughput Screening.

McAnally D, Siddiquee K, Sharir H, Qi F, Phatak S, Li JL, Berg E, Fishman J, Smith L.

SLAS Discov. 2017 Aug;22(7):867-878. doi: 10.1177/2472555217699158. Epub 2017 Mar 17.

PMID:
28314120
9.

GPCR structure and function relationship: identification of a biased apelin receptor mutant.

Ban T, Li X, Ma X, Yang H, Song Y, Sun Y, Shen M, Li N, Zhang MY, Ma Y, Zhong W, Zhang M, Hu LA.

Biochem J. 2018 Dec 6;475(23):3813-3826. doi: 10.1042/BCJ20180740.

PMID:
30409826
10.

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP.

Hypertension. 2015 Apr;65(4):834-40. doi: 10.1161/HYPERTENSIONAHA.114.05099. Epub 2015 Feb 23.

11.

Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin.

Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Darker JG.

J Neurochem. 2003 Mar;84(5):1162-72.

12.

[Functional dissociation between apelin receptor signaling and endocytosis: implications for the effects of apelin on arterial blood pressure].

Iturrioz X, El Messari S, De Mota N, Fassot C, Alvear-Perez R, Maigret B, Llorens-Cortes C.

Arch Mal Coeur Vaiss. 2007 Aug;100(8):704-8. French.

PMID:
17928781
13.

Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.

Murza A, Sainsily X, Coquerel D, Côté J, Marx P, Besserer-Offroy É, Longpré JM, Lainé J, Reversade B, Salvail D, Leduc R, Dumaine R, Lesur O, Auger-Messier M, Sarret P, Marsault É.

J Med Chem. 2016 Apr 14;59(7):2962-72. doi: 10.1021/acs.jmedchem.5b01549. Epub 2016 Mar 30.

PMID:
26986036
14.

Elucidation of the structure-activity relationships of apelin: influence of unnatural amino acids on binding, signaling, and plasma stability.

Murza A, Parent A, Besserer-Offroy E, Tremblay H, Karadereye F, Beaudet N, Leduc R, Sarret P, Marsault É.

ChemMedChem. 2012 Feb 6;7(2):318-25. doi: 10.1002/cmdc.201100492. Epub 2011 Dec 13.

PMID:
22170700
15.

Identifying structural determinants of potency for analogs of apelin-13: integration of C-terminal truncation with structure-activity.

Zhang Y, Maitra R, Harris DL, Dhungana S, Snyder R, Runyon SP.

Bioorg Med Chem. 2014 Jun 1;22(11):2992-7. doi: 10.1016/j.bmc.2014.04.001. Epub 2014 Apr 13.

PMID:
24755525
16.

Bioactivity of the putative apelin proprotein expands the repertoire of apelin receptor ligands.

Shin K, Chapman NA, Sarker M, Kenward C, Huang SK, Weatherbee-Martin N, Pandey A, Dupré DJ, Rainey JK.

Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1901-1912. doi: 10.1016/j.bbagen.2017.05.017. Epub 2017 May 22.

17.

Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation.

McKinnie SMK, Wang W, Fischer C, McDonald T, Kalin KR, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC.

J Med Chem. 2017 Jul 27;60(14):6408-6427. doi: 10.1021/acs.jmedchem.7b00723. Epub 2017 Jul 7.

PMID:
28685579
18.

Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression.

Atluri P, Morine KJ, Liao GP, Panlilio CM, Berry MF, Hsu VM, Hiesinger W, Cohen JE, Joseph Woo Y.

Cell Mol Biol Lett. 2007;12(1):127-38. Epub 2006 Nov 19.

19.

Agonist-induced internalization and desensitization of the apelin receptor.

Pope GR, Tilve S, McArdle CA, Lolait SJ, O'Carroll AM.

Mol Cell Endocrinol. 2016 Dec 5;437:108-119. doi: 10.1016/j.mce.2016.07.040. Epub 2016 Aug 1.

20.

The role of apelin in central cardiovascular regulation in rats with post-infarct heart failure maintained on a normal fat or high fat diet.

Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Fus L, Puchalska L, Gondek A, Dobruch J, Gomolka R, Wrzesien R, Zera T, Gornicka B, Kuch M.

Clin Exp Pharmacol Physiol. 2016 Oct;43(10):983-94. doi: 10.1111/1440-1681.12617.

PMID:
27378063

Supplemental Content

Support Center